Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or beta-thalassemia

15 Mar 1993

Abstract excerpt

Hydroxyurea (HU), an inhibitor of DNA synthesis, has been shown to increase fetal hemoglobin (HbF) levels in patients with sickle cell anemia and in some patients with beta-thalassemia. However, until now there have not been good in vitro model systems that simulate this effect for study of the molecular and cellular mechanism(s) involved in perturbing the normal ontogeny of the globin genes. We analyzed the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Hemoglobinopathies and Related Disorders
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 7680923
DOI: 10.1182/blood.v81.6.1630.1630

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or beta-thalassemiaPMID 7680923Read ↗

Mechanism for fetal hemoglobin induction by hydroxyurea in sickle cell erythroid progenitorsSemantic proximity Read ↗

Fetal Hemoglobin in Sickle Cell Anemia: Determinants of Response to HydroxyureaSemantic proximity Read ↗

Hematologic Responses of Patients with Sickle Cell Disease to Treatment with HydroxyureaSemantic proximity Read ↗

Hydroxyurea Treatment for Sickle Cell DiseaseSemantic proximity Read ↗

Fetal Hemoglobin and F-Cell Responses to Long-Term Hydroxyurea Treatment in Young Sickle Cell PatientsSemantic proximity Read ↗

Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse modelSemantic proximity Read ↗

Treatment of Sickle Cell Anemia with Hydroxyurea and ErythropoietinSemantic proximity Read ↗

Hemin-induced acceleration of hemoglobin production in immature cultured erythroid cells: preferential enhancement of fetal hemoglobinSemantic proximity Read ↗

Mean Corpuscular Hemoglobin Modulates HbF /F‐Cell and Clinical Response to Gene Therapy and Hydroxyurea in Sickle Cell DiseaseSemantic proximity Read ↗

Therapeutic Approaches to Hemoglobin Switching in Treatment of HemoglobinopathiesSemantic proximity Read ↗

Hydroxyurea down‐regulates <i>BCL11A, KLF</i>‐<i>1</i> and <i>MYB</i> through miRNA‐mediated actions to induce γ‐globin expression: implications for new therapeutic approaches of sickle cell diseaseSemantic proximity Read ↗

Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell AnemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.